ArticleBMC cancer2025
Safety and efficacy of toripalimab plus concurrent chemoradiotherapy for locally advanced cervical cancer: a single-arm, phase Ib trial.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04368273 (Phase I Study of Toripalimab Injection), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.
Who cites it
1 citing paper in PubMed.
- Virus-driven remodeling of the immune microenvironment and response to immune checkpoint inhibitors: the infection- immunity-cancer crosstalk.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAlthough two pivotal phase III trials have evaluated the efficacy of adding immune-checkpoint inhibitors (ICIs) to concurrent chemoradiotherapy (CCRT) in locally advanced cervical cancer (LACC), discrepancies between the two studies highlight the need for further exploration of ICIs combined with CCRT in this setting.
methodsTotally 30 patients with FIGO 2018 stage IB3-IVA cervical cancer were enrolled in this study. All patients underwent pelvic external beam radiotherapy (50.4 Gy in 28 fractions) followed by brachytherapy (30-36 Gy in 5-6 fractions), concurrent with cisplatin (40 mg/m² weekly) and toripalimab (240 mg every two weeks). The primary endpoint was adverse events, and secondary endpoints included the objective response rate (ORR) and progression-free survival (PFS). This trial is registered at ClinicalTrials.gov (NCT04368273) on April 25, 2020.
resultsTwenty-four patients (80%) experienced grade 3 or higher treatment-related adverse events (TRAEs). The most frequent ≥ grade 3 TRAEs were leukopenia (63%), lymphopenia (37%), and anemia (27%). One patient discontinued treatment due to immune-related hemophagocytic lymphohistiocytosis (HLH). Twenty patients (66.7%) experienced late radiation-related toxicities, including rectal hemorrhage (53.3%), hematuria (10%), and peripheral sensory neuropathy (13.3%). No treatment-related death occurred. All patients showed an ORR of 100% (95% [CI]: 0.85.9-1) as their best response. The 2-year PFS was 90% (95% CI 0.72-0.96). The median PFS was not reached with a 27.3-month follow-up.
conclusionsCombining toripalimab with CCRT had promising activity in LACC patients but might aggravate radiation-related adverse events and even cause serious immune-related adverse events. Therefore, ICIs therapy with CCRT needs further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.